Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) has been well established in controlled clinical trials. This study was designed to assess the use of MP29-02 and its effectiveness in routine clinical practice. This was a German multicenter, prospective, noninterventional study, including 1781 allergic rhinitis (AR) patients. Eligible patients (i.e., acute AR symptoms and visual analog scale [VAS] score >50 mm) were included, assigned MP29-02 at baseline, and reassessed after ∼14 days. Patients assessed symptom control using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP29-02 use, on days 0, 1, 3, and 7 and after ∼ 14 days. Patients' perceived levels of disease control were assessed on day 3. The Youden index determined patient-reported VAS score cutoffs on day 3 for "well controlled" and "partly controlled." MP29-02 reduced the VAS score from 75.4 mm (SD = 17.2) at baseline to 21.3 mm (SD = 18.3) by the last visit, a shift of 54.1 mm (SD = 24.6). One in every two patients felt their symptoms were well controlled at day 3. This perception of well-controlled symptoms at day 3 corresponded to an optimal VAS cutoff of 36 mm. On average, patients treated with MP29-02 crossed this well-controlled VAS cutoff by last visit. Similar results were found in adolescents, adults, and older adults, in those with perennial AR (PAR), seasonal AR (SAR), or PAR + SAR and in those with more and less severe disease. MP29-02 provides effective and rapid symptom control across all age groups in a real-life setting with responder rates higher than those observed in controlled clinical trials, supporting MP29-02's position as the drug of choice for the treatment for AR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impact of Allergic Rhinitis Symptoms on Quality of Life in Primary Care
Bousquet, P. J., Demoly, P., Devillier, P., Mesbah, K., & Bousquet, J. (2013) · International Archives of Allergy and Immunology · doi:10.1159/000342991 · Cited by 204
Self-citationAllergic rhinitis and the common cold – high cost to society
Hellgren, J., Cervin, A., Nordling, S., Bergman, A., & Cardell, L. O. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02269.x · Cited by 183
Cited by
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Self-citationInternational consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Klimek, L., Bergmann, K.-C., Biedermann, T., Bousquet, J., Hellings, P., Jung, K., Merk, H., Olze, H., Schlenter, W., Stock, P., et al. (2017) · Allergo Journal International · doi:10.1007/s40629-016-0006-7 · Cited by 475
Self-citationMACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
Bousquet, J., Schünemann, H. J., Hellings, P. W., Arnavielhe, S., Bachert, C., Bedbrook, A., Bergmann, K.-C., Bosnic-Anticevich, S., Brozek, J., Calderon, M., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.025 · Cited by 168
Self-citationThe hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
Price, D., Scadding, G., Ryan, D., Bachert, C., Canonica, G. W., Mullol, J., Klimek, L., Pitman, R., Acaster, S., Murray, R., et al. (2015) · Clinical and Translational Allergy · doi:10.1186/s13601-015-0083-6 · Cited by 105
“MP29-02, comprising azelastine hydrochloride, fluticasone propionate and a novel formulation in a single spray, is the newest addition to the AR treatment arsenal and is promising in this regard [39, 42].”
BackgroundSelf-citation
Metadata
- Authors
- Klimek, L., Bachert, C., Mösges, R., Munzel, U., Price, D., Virchow, J. C., Wahn, U., & Bousquet, J.
- Venue
- Allergy and Asthma Proceedings
- Publisher
- Oceanside Publications Inc.
- Published
- 2015-01-01
- Volume
- 36
- Issue
- 1
- Pages
- 40-47
- ISSN
- 1088-5412 (ISSN-L)
- OpenAlex
- W2043376405
- Cited by
- 58
- References
- 2
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.